Literature DB >> 16352469

Safety of ESAT-6.

Henrik Aggerbeck1, Søren M Madsen.   

Abstract

A recombinant dimer of the Mycobacterium tuberculosis (MTb) 6 kDa early secreted antigenic target (ESAT-6) was produced in Lactococcus lactis. Pharmacodynamic and safety studies were carried out in guinea pigs, rats, mice and dogs with intradermal (id), subcutaneous (sc) and intravenous (iv) administration of the antigen. In contrast to tuberculin purified protein derivative (PPD) the recombinant dimer (rdESAT-6) was able to discriminate MTb infection from BCG vaccination in vivo. In guinea pigs sensitized by infection with MTb, 1 microg rdESAT-6 gave a mean delayed-type hypersensitivity (DTH) response of 22 mm, a significantly stronger reaction than in animals sensitised by the environmental mycobacteria M. kansasii, M. szulgai and M. marinum. rdESAT-6 proved to be a safe tuberculin reagent in a dose range of 1-1000 microg with no or only minor local reactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352469     DOI: 10.1016/j.tube.2005.08.020

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

1.  Development of a skin test for bovine tuberculosis for differentiating infected from vaccinated animals.

Authors:  Adam O Whelan; Derek Clifford; Bhagwati Upadhyay; Eleanor L Breadon; James McNair; Glyn R Hewinson; Martin H Vordermeier
Journal:  J Clin Microbiol       Date:  2010-06-30       Impact factor: 5.948

Review 2.  Purified protein derivatives of tuberculin--past, present, and future.

Authors:  Hongliang Yang; Nicole A Kruh-Garcia; Karen M Dobos
Journal:  FEMS Immunol Med Microbiol       Date:  2012-08-01

3.  First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent.

Authors:  Winnie Bergstedt; Pernille N Tingskov; Birgit Thierry-Carstensen; Søren T Hoff; Henrik Aggerbeck; Vibeke O Thomsen; Peter Andersen; Aase B Andersen
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

4.  Low cross-reactivity of T-cell responses against lipids from Mycobacterium bovis and M. avium paratuberculosis during natural infection.

Authors:  Ildiko Van Rhijn; Thi Kim Anh Nguyen; Anita Michel; Dave Cooper; Marc Govaerts; Tan-Yun Cheng; Willem van Eden; D Branch Moody; Jacobus A W Coetzer; Victor Rutten; Ad P Koets
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

5.  Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection.

Authors:  Henrik Aggerbeck; Rafaela Giemza; Paulatsya Joshi; Pernille N Tingskov; Søren T Hoff; Julia Boyle; Peter Andersen; David J M Lewis
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

Review 6.  The Role of NRF2 in Mycobacterial Infection.

Authors:  Masashi Matsuyama; Mizu Nonaka; Masayuki Nakajima; Yuko Morishima; Yukio Ishii; Nobuyuki Hizawa
Journal:  Antioxidants (Basel)       Date:  2021-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.